Mar 10 2026
This announcement appears in BioMarin’s 2025 full-year financial report: “Following the company’s October announcement to explore options to divest ROCTAVIAN, BioMarin undertook a comprehensive effort to identify a potential buyer. Despite these efforts, BioMarin was unable to identify a qualified buyer and has decided to withdraw ROCTAVIAN from the market voluntarily.” There are no FVIII gene transfer therapies currently available. However, research continues to develop an effective AAV-like vector and a synthetic “gain of function” FVIII.
Comments (0)
Bleeding Disorders
No comments here.